摘要
目的通过检测血清HBVDNA，ALT和HBeAg滴度变化来预测恩替卡韦（ETV）治疗慢性乙型肝炎的临床疗效。方法60例慢性乙型肝炎患者接受ETV0．5mg／d，采用实时荧光定量PCR法检测服药后3，6和12个月时HBVDNA，ALT阴转率；采用免疫化学发光法检测血清治疗前后HBeAg滴度的变化。结果治疗12个月时，血清ALT复常率，HBeAg阴转率，HBeAg转换率分别为91．7％，86．7％和16．7％；患者基线HBeAg滴度与疗程3个月时HBeAg滴度下降幅度与远期的HBeAg转换率明显相关，HBeAg的基线滴度越低，HBeAg血清转换越高，与其他各组差异有统计学显著性意义；HBeAg滴度下降幅度≥90％的患者的HBeAg转换率明显高于〈90％的患者，与其他各组差异有统计学显著性意义。结论通过检测HBeAg滴度下降幅度可以早期预测ETV治疗HBeAg阳性CHB患者的HBeAg血清转换率。
Objective To evaluate the efficiency of entecavir in chronic hepatitis B （CHB） patients. Meathods 60 cases of patients treated with entecavir 0.5 mg/d. Observed the negative rate of HBV DNA and ALT after 3,6 and 12 months. Used immuno chemiluminescence to observe the HBeAg titer after medication, Results The negative rate of ALT and HBeAg, HBeAg conversion rate were 91.7% ,86.7% and 16.7% ,respectively. The titer of HBeAg was low at baseline,the patients would had higher HBeAg seroconversion,there were significant differences with other groups. The titer of HBeAg decreased ≥90% patients was significantly higher in patients with 〈90% on the 3 months. Conclusion The HBeAg titer could be predicted ETV for treatment of HBeAg positive CHB patients.
出处
《现代检验医学杂志》
CAS
2015年第2期142-143,共2页
Journal of Modern Laboratory Medicine
